Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.
Free White Paper
Partnering Activity Increases 40% at ChinaBio® Partnering Forum
publication date: May 24, 2012
author/source: Richard Daverman, PhD
ChinaBio® LLC and EBD Group, co-producers of the ChinaBio® Partnering Forum, held May 22-24 in Suzhou, today announced that the fourth edition of the event attracted 719 attendees from 432 companies and 23 countries who engaged in more than 1100 one-to-one meetings. These results position ChinaBio® Partnering Forum as the largest and most productive life science conference in China.
ChinaBio® Partnering Forum was created to bring together global pharma and biotech companies from Europe, the United States and around the world seeking partnerships with China life science companies.
The theme of this year’s ChinaBio® Partnering Forum was “Going Global” to reflect the increase in cross-border activity between Chinese and Western companies. Keynote speakers from Bayer, Merck, Pfizer, Lily and Hengrui reflect both that Western pharma are significantly increasing their focus on China, while Chinese pharma are also taking their products to the global market.
Showcasing China’s commitment to innovation, the event’s Innovation Showcase featured, for the first time, recipients of China’s prestigious Thousand Talents Program Award. These leading scientists and entrepreneurs presented novel technologies for new drugs, diagnostics and research technologies.
On a parallel track, 38 life science companies presented detailed overviews of their technologies and business strategies to prospective partners and investors. Among the presenting companies were several of China’s largest and most innovative pharmaceutical companies, including Ascletis, Fosun, BeiGene, Hua Medicine and Hutchison MediPharma.
“It was very exciting to set a new attendance record at our fourth ChinaBio® Partnering Forum,” said Greg Scott, CEO and founder of ChinaBio® LLC. “But more importantly, the quality of the companies and attendees continues to rise. With approximately one-third of our attendees from outside China, the ChinaBio® Partnering Forum is now the largest and most international conference focused on life science in China.”
“We were very pleased by the high level of partnering activity at the conference,” added Carola Schropp, President of EBD Group. “With over 3,000 meeting requests and over 1,100 one-to-one meetings, it’s apparent that our Chinese participants are successfully leveraging our partneringONE® system to identify potential partners from around the world.”
Partnering has become a significant component of China’s explosive biopharma industry. The number of partnering deals grew 15% last year, with co-development deals the fastest growing segment, according to data from ChinaBio LLC’s research team. The rapid increase has been driven by China’s robust pipeline of over 3,200 novel molecules, nearly 200 of which are in clinical development.
Next year, the Fifth Annual ChinaBio® Partnering Forum will be held in Beijing, and is expected to approach 800 attendees. More information about both this year’s and next year’s events is available at www.ebdgroup.com/cbpf.
ChinaBio® in the News
Hong Kong, China
May 5–6, 2016